Description: Homo sapiens phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), mRNA. RefSeq Summary (NM_006218): Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016]. Sequence Note: This RefSeq record was created from transcript and genomic sequence data to make the sequence consistent with the reference genome assembly. The genomic coordinates used for the transcript record were based on transcript alignments. Transcript (Including UTRs) Position: hg19 chr3:178,866,311-178,952,497 Size: 86,187 Total Exon Count: 21 Strand: + Coding Region Position: hg19 chr3:178,916,614-178,952,152 Size: 35,539 Coding Exon Count: 20
ID:PK3CA_HUMAN DESCRIPTION: RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Short=PI3-kinase subunit alpha; Short=PI3K-alpha; Short=PI3Kalpha; Short=PtdIns-3-kinase subunit alpha; EC=2.7.1.153; AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; Short=PtdIns-3-kinase subunit p110-alpha; Short=p110alpha; AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide; AltName: Full=Serine/threonine protein kinase PIK3CA; EC=2.7.11.1; FUNCTION: Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4- phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5- bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation in breast cancer cells through the PDPK1- AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Has also serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS. CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5- bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5- trisphosphate. CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein. SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with IRS1 in nuclear extracts. Interacts with RUFY3 (By similarity). Interacts with RASD2 (By similarity). Interacts with APPL1. Interacts with HRAS1 and KRAS (By similarity). Interaction with HRAS1/KRAS is required for PI3K pathway signaling and cell proliferation stimulated by EGF and FGF2 (By similarity). INTERACTION: P27986:PIK3R1; NbExp=2; IntAct=EBI-2116585, EBI-79464; DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with the PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the recruitment to the plasma membrane. The inhibitory interactions with PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with the nSH2 (N-terminal SH2) region of PIK3R1. DISEASE: Note=Most of the cancer-derived mutations are missense mutations and map to one of the three hotspots: Glu-542; Glu-545 and His-1047. Mutated isoforms participate in cellular transformation and tumorigenesis induced by oncogenic receptor tyrosine kinases (RTKs) and HRAS1/KRAS. Interaction with HRAS1/KRAS is required for Ras-driven tumor formation. Mutations increasing the lipid kinase activity are required for oncogenic signaling. The protein kinase activity may not be required for tumorigenesis. DISEASE: Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500]. DISEASE: Defects in PIK3CA are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. DISEASE: Defects in PIK3CA are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late- stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. DISEASE: Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550]. DISEASE: Defects in PIK3CA are a cause of keratosis seborrheic (KERSEB) [MIM:182000]. A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance. DISEASE: Defects in PIK3CA are the cause of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE) [MIM:612918]. CLOVE is a sporadically occurring, non-hereditary disorder characterized by asymmetric somatic hypertrophy and anomalies in multiple organs. It is defined by four main clinical findings: congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal/spinal abnormalities. The presence of truncal overgrowth and characteristic patterned macrodactyly at birth differentiates CLOVE from other syndromic forms of overgrowth. MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an oncogene derived from PIK3CA (PubMed:18418043). SIMILARITY: Belongs to the PI3/PI4-kinase family. SIMILARITY: Contains 1 C2 PI3K-type domain. SIMILARITY: Contains 1 PI3K-ABD domain. SIMILARITY: Contains 1 PI3K-RBD domain. SIMILARITY: Contains 1 PI3K/PI4K domain. SIMILARITY: Contains 1 PIK helical domain.
breast cancer , PIK3CA mutations in breast cancer are associated with poor outcome, Breast cancer research and treatment. 2005.
[PubMed 16317585]
Colonic Neoplasms Shuji Ogino , et al. Journal of clinical oncology 2009 27(9):1477-84, PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer., Journal of clinical oncology 2009 27(9):1477-84.
[PubMed 19237633]
colorectal cancer Kato, S. et al. 2007, PIK3CA mutation is predictive of poor survival in patients with colorectal cancer, Int J Cancer 2007.
[PubMed 17590872]
The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.
ModBase Predicted Comparative 3D Structure on P42336
Front
Top
Side
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.
Orthologous Genes in Other Species
Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
BioCarta from NCI Cancer Genome Anatomy Project h_eif4Pathway - Regulation of eIF4e and p70 S6 Kinase h_TPOPathway - TPO Signaling Pathway h_Par1Pathway - Thrombin signaling and protease-activated receptors h_egfPathway - EGF Signaling Pathway h_erk5Pathway - Role of Erk5 in Neuronal Survival h_ghPathway - Growth Hormone Signaling Pathway h_hdacPathway - Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK) h_aktPathway - AKT Signaling Pathway h_igf1mtorpathway - Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway h_mTORPathway - mTOR Signaling Pathway h_ptenPathway - PTEN dependent cell cycle arrest and apoptosis h_achPathway - Role of nicotinic acetylcholine receptors in the regulation of apoptosis h_arfPathway - Tumor Suppressor Arf Inhibits Ribosomal Biogenesis h_bcellsurvivalPathway - B Cell Survival Pathway h_insulinPathway - Insulin Signaling Pathway h_metPathway - Signaling of Hepatocyte Growth Factor Receptor h_ngfPathway - Nerve growth factor pathway (NGF) h_tcrPathway - T Cell Receptor Signaling Pathway h_vegfPathway - VEGF, Hypoxia, and Angiogenesis h_cdc42racPathway - Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration h_ctla4Pathway - The Co-Stimulatory Signal During T-cell Activation h_cxcr4Pathway - CXCR4 Signaling Pathway h_nkcellsPathway - Ras-Independent pathway in NK cell-mediated cytotoxicity h_ctcfPathway - CTCF: First Multivalent Nuclear Factor h_her2Pathway - Role of ERBB2 in Signal Transduction and Oncology h_igf1Pathway - IGF-1 Signaling Pathway h_plcPathway - Phospholipase C Signaling Pathway h_tffPathway - Trefoil Factors Initiate Mucosal Healing h_crebPathway - Transcription factor CREB and its extracellular signals h_ecmPathway - Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia h_il7Pathway - IL-7 Signal Transduction h_trkaPathway - Trka Receptor Signaling Pathway h_fcer1Pathway - Fc Epsilon Receptor I Signaling in Mast Cells h_hcmvPathway - Human Cytomegalovirus and Map Kinase Pathways h_rac1Pathway - Rac 1 cell motility signaling pathway h_edg1Pathway - Phospholipids as signalling intermediaries h_gcrPathway - Corticosteroids and cardioprotection h_gleevecpathway - Inhibition of Cellular Proliferation by Gleevec h_pdgfPathway - PDGF Signaling Pathway h_pparaPathway - Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) h_rasPathway - Ras Signaling Pathway h_RacCycDPathway - Influence of Ras and Rho proteins on G1 to S Transition h_gsk3Pathway - Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages h_igf1rPathway - Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation h_badPathway - Regulation of BAD phosphorylation h_il2rbPathway - IL-2 Receptor Beta Chain in T cell Activation h_longevityPathway - The IGF-1 Receptor and Longevity h_nfatPathway - NFAT and Hypertrophy of the heart (Transcription in the broken heart)
Reactome (by CSHL, EBI, and GO)
Protein P42336 (Reactome details) participates in the following event(s):
R-HSA-1226012 Binding of PI3K p110 subunit alpha (PIK3CA) to complex of GRB2:GAB1:PIK3R1 and ligand-responsive p-6Y-EGFR mutants R-HSA-1250372 Recruitment of PI3K subunit p110 (PIK3CA) to PI3K subunit p85 (PIK3R1) bound to p-ERBB4cyt1 homodimers R-HSA-1839080 Activated cytosolic FGFR1 fusions bind PIK3CA R-HSA-1839102 BCR-FGFR1 fusion:GRB2:p-GAB2:PIK3R1 binds PIK3CA R-HSA-5637765 Binding of PI3K p110 subunit alpha (PIK3CA) to complex of GRB2:GAB1:PIK3R1 and p-EGFRvIII R-HSA-5654591 Activated FGFR1:p-FRS2:GRB2:GAB1:PI3KR1 binds PIK3CA R-HSA-5654596 Activated FGFR1:p-FRS2:p-PPTN11:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-5654614 Activated FGFR2:p-FRS2:GRB2:GAB1:PI3KR1 binds PIK3CA R-HSA-5654622 Activated FGFR2:p-FRS2:p-PPTN11:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-5654640 Activated FGFR3:p-FRS2:GRB2:GAB1:PI3KR1 binds PIK3CA R-HSA-5654643 Activated FGFR3:p-FRS2:p-PPTN11:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-5654662 Activated FGFR4:p-FRS2:GRB2:GAB1:PI3KR1 binds PIK3CA R-HSA-5654669 Activated FGFR4:p-FRS2:p-PPTN11:GRB2:GAB1:PIK3R1binds PIK3CA R-HSA-5655245 Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-5655252 Activated FGFR4 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-5655263 Activated FGFR1 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-5655285 Activated FGFR3 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-8853308 Activated FGFR3 fusions:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA R-HSA-114542 Rac1 activation of PI3K R-HSA-205262 Direct recruitment of PI3K to p-KIT R-HSA-388830 PI3K binds ICOS R-HSA-388832 PI3K binds CD28 R-HSA-416358 G alpha (q) inhibits PI3K alpha R-HSA-1562641 Indirect recruitment of PI3K to KIT via p(Y)-GAB2 R-HSA-1250189 Binding of PI3K to ERBB2:P-ERBB3 heterodimer R-HSA-1306965 Binding of PI3K to GRB2:GAB1 in complex with phosphorylated heterodimer of ERBB2 and EGFR. R-HSA-177927 PI3K binds to EGF:EGFR:GRB2:GAB1 R-HSA-1250346 Binding of PI3K to p-ERBB2:p-ERBB4 CYT-1 heterodimers R-HSA-8851954 Phosphorylated GAB1 recruits PI3K to MET R-HSA-508247 Gab2 binds the p85 subunit of Class 1A PI3 kinases R-HSA-879917 CBL, GRB2, FYN and PI3K p85 subunit are constitutively associated R-HSA-914182 14-3-3 zeta binding allows recruitment of PI3K R-HSA-1226014 Conversion of PIP2 to PIP3 by PI3K bound to ligand-responsive p-6Y-EGFR mutants R-HSA-1250370 Conversion of PIP2 into PIP3 by PI3K bound to p-ERBB4cyt1 homodimers R-HSA-1250462 PIP2 to PIP3 conversion by PI3K bound to phosphorylated heterodimer of ERBB2 and ERBB3 R-HSA-1306957 PIP2 to PIP3 conversion by PI3K bound to GRB2:GAB1 in complex with phosphorylated heterodimer of ERBB2 and EGFR R-HSA-1839107 BCR-FGFR1-associated PI3K phosphorylates PIP2 to PIP3. R-HSA-1839091 Cytosolic FGFR1 fusion protein-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5637801 Conversion of PIP2 to PIP3 by PI3K bound to phosphorylated EGFRvIII R-HSA-5654717 FGFR4-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5654692 FGFR1- and PTPN11- associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5654701 FGFR2-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5654697 FGFR2- and PTPN11- associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5654705 FGFR3-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5654709 FGFR3- and PTPN11-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5654690 FGFR1-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5654714 FGFR4- and PTPN11-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5655290 Activated FGFR1 mutant-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5655235 Activated FGFR4 mutant-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5655289 Activated FGFR3 mutant-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-5655323 Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-8853323 Activated FGFR3 fusion-associated PI3K phosphorylates PIP2 to PIP3 R-HSA-74737 p-Y-IRS1,p-Y-IRS2 bind PI3K R-HSA-186780 PI3-kinase binds to the active receptor R-HSA-198315 Active IRS recruits PI3K to the plasma membrane and activates it R-HSA-202203 Recruitment of PI3K to plasma membrane R-HSA-204798 Interaction of Tie2 and p85 of PI3K R-HSA-451758 p85 associates with both p-Nephrin and CD2AP R-HSA-2029273 PI3K binds to p-6Y-SYK R-HSA-2424482 p85 regulatory unit of PI3K binds p-6Y-SYK R-HSA-2730842 PI3K associates with phosphorylated GAB2 R-HSA-5218852 p-6Y-VEGFR2 binds PI3K R-HSA-5357479 p-AXL binds PI3K R-HSA-389158 CD28 bound PI3K phosphorylates PIP2 to PIP3 R-HSA-437162 PI3K alpha, beta, gamma convert PIP2 to PIP3 R-HSA-912629 CBL is tyrosine phosphorylated R-HSA-2400009 PI3K inhibitors block PI3K catalytic activity R-HSA-2316434 PI3K phosphorylates PIP2 to PIP3 R-HSA-1676109 PI4P is phosphorylated to PI(3,4)P2 by PI3K3C[2] at the plasma membrane R-HSA-1676048 PI(4,5)P2 is phosphorylated to PI(3,4,5)P3 by PIK3C[1] at the plasma membrane R-HSA-177939 PI3K converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) R-HSA-1306979 PIP2 to PIP3 conversion by PI3K bound to phosphorylated heterodimer of ERBB2 and ERBB4 CYT1 R-HSA-8852019 MET bound PI3K generates PIP3 R-HSA-2394007 PI3K gain of function mutants phosphorylate PIP2 to PIP3 R-HSA-1433514 Synthesis of PIP3 from PIP2 by PI3K R-HSA-186800 PI3K catalyses the phosphorylation of PIP2 to PIP3 R-HSA-198266 PI3K produces PIP3 and other phosphatidyl inositides R-HSA-202365 PI3K bound to TRAT1 phosphorylates PIP2 to PIP3 R-HSA-2029271 PI3K phosphorylates PIP2 to PIP3 R-HSA-2424480 PI3K phosphorylates PIP2 to PIP3 R-HSA-2730870 Phosphorylation of PIP2 to PIP3 by PI3K R-HSA-109699 PI3K-containing complexes phosphorylate PIP2 to PIP3 R-HSA-5218819 VEGFA dimer:p-6Y-VEGFR2 dimer:PI3K phosphorylates PIP2 to PIP3 R-HSA-1236382 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants R-HSA-1250342 PI3K events in ERBB4 signaling R-HSA-1839117 Signaling by cytosolic FGFR1 fusion mutants R-HSA-5637810 Constitutive Signaling by EGFRvIII R-HSA-5654689 PI-3K cascade:FGFR1 R-HSA-5654695 PI-3K cascade:FGFR2 R-HSA-5654710 PI-3K cascade:FGFR3 R-HSA-5654720 PI-3K cascade:FGFR4 R-HSA-5655253 Signaling by FGFR2 in disease R-HSA-5655291 Signaling by FGFR4 in disease R-HSA-5655302 Signaling by FGFR1 in disease R-HSA-8853338 Signaling by FGFR3 point mutants in cancer R-HSA-8853334 Signaling by FGFR3 fusions in cancer R-HSA-416482 G alpha (12/13) signalling events R-HSA-1433557 Signaling by SCF-KIT R-HSA-388841 Costimulation by the CD28 family R-HSA-389357 CD28 dependent PI3K/Akt signaling R-HSA-416476 G alpha (q) signalling events R-HSA-1963642 PI3K events in ERBB2 signaling R-HSA-180292 GAB1 signalosome R-HSA-8851907 MET activates PI3K/AKT signaling R-HSA-9028335 Activated NTRK2 signals through PI3K R-HSA-5637815 Signaling by Ligand-Responsive EGFR Variants in Cancer R-HSA-1236394 Signaling by ERBB4 R-HSA-1839124 FGFR1 mutant receptor activation R-HSA-5637812 Signaling by EGFRvIII in Cancer R-HSA-5654687 Downstream signaling of activated FGFR1 R-HSA-5654696 Downstream signaling of activated FGFR2 R-HSA-5654708 Downstream signaling of activated FGFR3 R-HSA-5654716 Downstream signaling of activated FGFR4 R-HSA-1226099 Signaling by FGFR in disease R-HSA-5655332 Signaling by FGFR3 in disease R-HSA-912526 Interleukin receptor SHC signaling R-HSA-912631 Regulation of signaling by CBL R-HSA-512988 Interleukin-3, 5 and GM-CSF signaling R-HSA-8853659 RET signaling R-HSA-388396 GPCR downstream signalling R-HSA-9006934 Signaling by Receptor Tyrosine Kinases R-HSA-1280218 Adaptive Immune System R-HSA-389356 CD28 co-stimulation R-HSA-1227986 Signaling by ERBB2 R-HSA-177929 Signaling by EGFR R-HSA-6806834 Signaling by MET R-HSA-9006115 Signaling by NTRK2 (TRKB) R-HSA-109704 PI3K Cascade R-HSA-186763 Downstream signal transduction R-HSA-198203 PI3K/AKT activation R-HSA-202424 Downstream TCR signaling R-HSA-210993 Tie2 Signaling R-HSA-373753 Nephrin family interactions R-HSA-2029485 Role of phospholipids in phagocytosis R-HSA-2424491 DAP12 signaling R-HSA-2730905 Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-4420097 VEGFA-VEGFR2 Pathway R-HSA-1643713 Signaling by EGFR in Cancer R-HSA-5654736 Signaling by FGFR1 R-HSA-5654738 Signaling by FGFR2 R-HSA-5654741 Signaling by FGFR3 R-HSA-5654743 Signaling by FGFR4 R-HSA-5663202 Diseases of signal transduction R-HSA-114604 GPVI-mediated activation cascade R-HSA-451927 Interleukin-2 family signaling R-HSA-449147 Signaling by Interleukins R-HSA-422475 Axon guidance R-HSA-372790 Signaling by GPCR R-HSA-162582 Signal Transduction R-HSA-168256 Immune System R-HSA-2219530 Constitutive Signaling by Aberrant PI3K in Cancer R-HSA-1257604 PIP3 activates AKT signaling R-HSA-6811558 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling R-HSA-1660499 Synthesis of PIPs at the plasma membrane R-HSA-166520 Signaling by NTRKs R-HSA-112399 IRS-mediated signalling R-HSA-186797 Signaling by PDGF R-HSA-187037 Signaling by NTRK1 (TRKA) R-HSA-202403 TCR signaling R-HSA-202733 Cell surface interactions at the vascular wall R-HSA-1500931 Cell-Cell communication R-HSA-2029480 Fcgamma receptor (FCGR) dependent phagocytosis R-HSA-2172127 DAP12 interactions R-HSA-2454202 Fc epsilon receptor (FCERI) signaling R-HSA-194138 Signaling by VEGF R-HSA-190236 Signaling by FGFR R-HSA-1643685 Disease R-HSA-76002 Platelet activation, signaling and aggregation R-HSA-1280215 Cytokine Signaling in Immune system R-HSA-1266738 Developmental Biology R-HSA-2219528 PI3K/AKT Signaling in Cancer R-HSA-9006925 Intracellular signaling by second messengers R-HSA-199418 Negative regulation of the PI3K/AKT network R-HSA-1483255 PI Metabolism R-HSA-74751 Insulin receptor signalling cascade R-HSA-2428928 IRS-related events triggered by IGF1R R-HSA-109582 Hemostasis R-HSA-168249 Innate Immune System R-HSA-1483257 Phospholipid metabolism R-HSA-74752 Signaling by Insulin receptor R-HSA-2428924 IGF1R signaling cascade R-HSA-556833 Metabolism of lipids R-HSA-2404192 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-1430728 Metabolism
US Server
